<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="9459">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05697328</url>
  </required_header>
  <id_info>
    <org_study_id>22-10-01</org_study_id>
    <nct_id>NCT05697328</nct_id>
  </id_info>
  <brief_title>Barotrauma in Hyperbaric Oxygen Therapy</brief_title>
  <acronym>HBOT</acronym>
  <official_title>Pseudoephedrine Prophylaxis for Prevention of Middle Ear Barotrauma in Hyperbaric Oxygen Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>John Muir Health</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>John Muir Health</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research is to study whether the use of pseudoephedrine can help prevent&#xD;
      middle ear trauma during HBOT. Pseudoephedrine is an approved drug that is used for temporary&#xD;
      relief of nasal or sinus pain and pressure.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects will be asked to take a pill (pseudoephedrine or placebo) between 45 and 120 minutes&#xD;
      before hyperbaric oxygen therapy. Subjects' ears will be examined before and after therapy&#xD;
      and be asked to assess ear pain. There will be no further tests or procedures after&#xD;
      completion of therapy session and ear examinations.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2023</start_date>
  <completion_date type="Anticipated">January 2026</completion_date>
  <primary_completion_date type="Anticipated">January 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>prospective randomized double-blind placebo control study design (enrollment ratio 1:1)</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>double-blind placebo control</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Compare changes in self-reported ear pain during hyperbaric oxygen therapy</measure>
    <time_frame>45-60 minutes</time_frame>
    <description>Patients to describe pain on a numerical scale before, during and after hyperbaric oxygen therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of completed compression</measure>
    <time_frame>1 minute</time_frame>
    <description>Compare frequency of complete versus aborted hyperbaric oxygen therapy session due to pain.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Barotrauma</condition>
  <arm_group>
    <arm_group_label>Pseudoephedrine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>over the counter pseudoephedrine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>pharmacy created placebo capsule</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pseudoephedrine Pill</intervention_name>
    <description>One-time 60mg dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy</description>
    <arm_group_label>Pseudoephedrine</arm_group_label>
    <other_name>Sudafed</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>One time dose given orally between 45-120 minutes prior to hyperbaric oxygen therapy</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New patient requiring HBOT (either inpatient or outpatient)&#xD;
&#xD;
          -  Age greater than or equal to 18 years and less than 80 years&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Full decision capacity&#xD;
&#xD;
          -  Able and medically cleared to swallow a pill&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Enrollment would delay hyperbaric therapy more than 30 minutes in patients with&#xD;
             emergent indications (example: Central Retinal Arterial Occlusion, Carbon Monoxide,&#xD;
             Air Gas Embolism)&#xD;
&#xD;
          -  Contraindication to pseudoephedrine (monoamine oxidase inhibitors (MAOI) use,&#xD;
             pregnancy, glaucoma, heart disease, allergy to drug class)&#xD;
&#xD;
          -  Systolic Blood Pressure &gt;160&#xD;
&#xD;
          -  Diastolic Blood Pressure &gt; 90&#xD;
&#xD;
          -  Heart Rate &gt;100&#xD;
&#xD;
          -  Decongestant/antihistamine/pseudoephedrine/nasal steroid/oxymetazoline use within 12&#xD;
             hours.&#xD;
&#xD;
          -  Prisoner&#xD;
&#xD;
          -  Intubated&#xD;
&#xD;
          -  Unable to swallow oral medications&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacinta Showers, RN</last_name>
    <role>Principal Investigator</role>
    <affiliation>John Muir Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacinta Showers, RN</last_name>
    <phone>9259473212</phone>
    <email>jacinta.showers@johnmuirhealth.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Todd Kessinger, MD, MD</last_name>
    <phone>9259473212</phone>
    <email>todd.kessinger_MD@johnmuirhealth.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Muir Health</name>
      <address>
        <city>Walnut Creek</city>
        <state>California</state>
        <zip>94598</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacinta Showers, RN</last_name>
      <phone>925-947-3212</phone>
      <email>jacinta.showers@johnmuirhealth.com</email>
    </contact>
    <contact_backup>
      <last_name>Todd Kessinger, MD</last_name>
      <phone>9259473212</phone>
      <email>todd.kessinger_MD@johnmuirhealth.com</email>
    </contact_backup>
    <investigator>
      <last_name>Jacinta Showers, RN</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Todd Kessinger, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>December 26, 2022</study_first_submitted>
  <study_first_submitted_qc>January 16, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">January 25, 2023</study_first_posted>
  <last_update_submitted>March 8, 2023</last_update_submitted>
  <last_update_submitted_qc>March 8, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 10, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>John Muir Health</investigator_affiliation>
    <investigator_full_name>Jacinta Showers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>hyperbaric oxygen therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Barotrauma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pseudoephedrine</mesh_term>
    <mesh_term>Ephedrine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

